HeartBeam Q2 FY26 net loss narrows to $5 million; SG&A expenses rise to $2.76 million
BEAT•Q2 FY26 loss and expenses
HeartBeam posted a GAAP net loss of $5 million, or $(0.10) a share, in Q2 2026, versus a $5 million loss.
SG&A rose to $2.8 million from $1.7 million, due to $0.6 million stock-based compensation and $0.3 million severance accrual.
R&D fell to $2.3 million from $3.3 million, on lower product development and consulting costs tied to the HeartBeam System.
ALIGN-ACS enrollment completed early
ALIGN-ACS enrollment finished early at 134 patients; management said results are slated for presentation at TCT 2026.
Cash position improves after stock offering
Cash and cash equivalents climbed to $8.7 million at June 30 from $4.4 million at Dec. 31 after a $11.5 million stock offering.
